Insmed Stock News

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

BRIDGEWATER, N.J. , June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,

BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t

Insmed (INSM) announced positive topline results from an Aspen Phase 3 study of Brensocatib. Insmed is a biopharmaceutical company that develops therapies for patients with serious and rare diseases.

BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,

BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,

Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.

Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.

BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,

Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients wit

Michelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.

Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The compa

Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ra

Insmed stock catapulted Tuesday after the biotech company experimental lung disease treatment succeeded in a final-phase study.